Data at AAN showed Gilenya® high efficacy in achieving 'no evidence of disease activity' in previously-treated highly-active MS patients Novartis, 21 Apr 2015 Accessed on 21 Apr 2015 from http://www.novartis.com/newsroom/media-releases/en/2015/1912676.shtml. CommentRecommendBookmarkWatch